Johnson & Johnson plans to separate its orthopedics segment into its own business within 18 to 24 months, according to an Oct. 14 news release.
The company said it expects the move to improve top-line growth and operating margins in the orthopedics unit, which generated about $9.2 billion in sales in fiscal 2024. The business is to be named DePuy Synthes.
“Upon completion of the planned separation, DePuy Synthes would be the largest, most comprehensive orthopaedics-focused company, with leading market share positions across major product categories,” the release said.
In late 2021, J&J announced it would split itself into two companies, one for consumer health products and another for pharmaceuticals and medical devices.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
